The Technical Analyst
Select Language :
NuCana PLC [NCNA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

NuCana PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

NuCana PLC is listed at the  Exchange

-16.75% GBP0.260

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 13.61 mill
EPS: -0.670
P/E: -0.390
Earnings Date: May 14, 2024
SharesOutstanding: 52.36 mill
Avg Daily Volume: 1.626 mill
RATING 2024-03-28
B+
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.390 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.07x
Company: PE -0.390 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

GBP 0.227 - 0.293

( +/- 12.69%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - GBP0.255
Forecast 2: 16:00 - GBP0.255
Forecast 3: 16:00 - GBP0.255
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price GBP0.260 (-16.75% )
Volume 1.288 mill
Avg. Vol. 1.626 mill
% of Avg. Vol 79.22 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for NuCana PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for NuCana PLC

RSI

Intraday RSI14 chart for NuCana PLC

Last 10 Buy & Sell Signals For NCNA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            NuCana PLC

NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Last 10 Buy Signals

Date Signal @
THETAUSDMar 29 - 11:39$2.93
SNXUSDMar 29 - 11:40$4.77
HBTCUSDMar 29 - 11:3833 786
GMXUSDMar 29 - 11:3844.96
FARMUSDMar 29 - 11:4053.58
OMGUSDMar 29 - 11:39$1.120
RLCUSDMar 29 - 11:39$3.90
KSMUSDMar 29 - 11:39$49.80
HBARUSDMar 29 - 11:39$0.115
ENJUSDMar 29 - 11:39$0.491

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.